Screening Serum Proteins In Liver Cancer And Validation And Functional Study Of CCL15

Background and ObjectiveDiscovery of biomarkers by use of SELDI-TOF mass spectrometry in the sera from hepatocellular carcinoma and healthy people,to search tumor markers of hepatocellular carcinoma for diagnosis.MethodsPart1Discovery of biomarkers by use of SELDI-TOF mass spectrometry in the sera from hepatocellular carcinoma and healthy people.Part2For patients with liver cancer of high expression proteins 7777.27Da separation and mass spectrometry,identified as CCL15;follow-up by enzyme-linked immunosorbent assay(ELISA),serum CCL15 for HCC confirmed;also confirmed by immunohistochemistry of high expression of CCL15 for liver carcerPart3Through a series of cytological experiments confirmed the in vitro CCL15-CCR1 axis in liver cancer invasion and metastasis.Results1.We used SELDI-TOF-MS screening to seven different proteins,which we found mass to charge ratio 6489.48Da(P1),6662.34Da(P2),8593.75 Da(P4),8720.23 Da(P5)at four different protein content was significantly higher in normal group than in benign diseases group and liver cancer group,7777.27Da(P3)and 9250.OODa(P6)at two different protein content in hepatocellular carcinoma were significantly higher than in normal group and benign diseases group,16200.17 Da(P7)at the difference in protein content was significantly higher in benign diseases group than that of hepatocellular carcinoma and the normal group.2.7777.27Da protein was identified as CCL15.3.CCL15-CCR1 axis can promote invasion and metastasis of liver cancerConclusions1.High expression of CCL15 in serum may become an important diagnostic marker for hepatocellular carcinoma.2.CCL15-CCR1 axis was closely related with invasion and metastasis of liver cancer,and CCL15-CCR1 aixs may become drug target which inhibited metastasis and recurrence of liver cancer.